What is the current Price Target for the Vera Therapeutics Inc - Ordinary Shares - Class A stock?

The average Vera Therapeutics Inc - Ordinary Shares - Class A target price is $81.60. This is 150.77% higher than the current stock price. The highest price target is 222.68%, the lowest is 5.53%. 16 Analysts have issued a price target Vera Therapeutics Inc - Ordinary Shares - Class A 2027 .

What's going on with the Vera Therapeutics Inc - Ordinary Shares - Class A stock today?

The performance of Vera Therapeutics Inc - Ordinary Shares - Class A stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Vera Therapeutics Inc - Ordinary Shares - Class A Forecast, price target & analysts

Q: How high will the Vera Therapeutics Inc - Ordinary Shares - Class A stock rise?

No reliable answer can be given as to how high the Vera Therapeutics Inc - Ordinary Shares - Class A stock will rise. The performance of stocks, including the Vera Therapeutics Inc - Ordinary Shares - Class A stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

Q: Why did the Vera Therapeutics Inc - Ordinary Shares - Class A stock fall?

The decline in Vera Therapeutics Inc - Ordinary Shares - Class A stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

$32.54

2.40%

Nasdaq, Sep 25, 04:00 pm EDT. Closed.

ISIN

US92337R1014

Symbol

VERA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Analysts Charts Ownership News Strategies

Vera Therapeutics Inc - Ordinary Shares - Class A Target price 2026 - Analyst rating & recommendation

Vera Therapeutics Inc - Ordinary Shares - Class A Classifications & Recommendation

Buy

90%

Hold

10%

Vera Therapeutics Inc - Ordinary Shares - Class A Price Target

Target Price	$81.60
Price	$32.54
Potential	150.77% register free of charge
Number of Estimates	16

	16 Analysts have issued a price target Vera Therapeutics Inc - Ordinary Shares - Class A 2027 . The average Vera Therapeutics Inc - Ordinary Shares - Class A target price is $81.60. This is 150.77% register free of charge higher than the current stock price. The highest price target is $105.00 222.68% register free of charge , the lowest is $34.34 5.53% register free of charge .
	A rating was issued by 20 analysts: 18 Analysts recommend Vera Therapeutics Inc - Ordinary Shares - Class A to buy, 2 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Vera Therapeutics Inc - Ordinary Shares - Class A stock has an average upside potential 2027 of 150.77% register free of charge . Most analysts recommend the Vera Therapeutics Inc - Ordinary Shares - Class A stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '25	2026 Estimates
Earnings Per Share $	-4.66	-6.26
	69.45%	34.33%
P/E		negative
EV/Sales		62.83

14 Analysts have issued a Vera Therapeutics Inc - Ordinary Shares - Class A forecast for earnings per share. The average Vera Therapeutics Inc - Ordinary Shares - Class A EPS is

unlock

. This is

unlock

than earnings per share in the financial year 2025. The highest EPS forecast is

unlock

, the lowest is

unlock

This results in the following potential growth metrics and future valuations:

2025	$-4.66	69.45%
2026	$-6.26 34.33% unlock
2027	$-4.19 33.07% unlock
2028	$0.37 108.83% unlock
2029	$4.62 1,148.65% unlock
2030	$7.57 63.85% unlock
2031	$11.13 47.03% unlock
2032	$11.42 2.61% unlock
2033	$13.20 15.59% unlock

Current	-5.82	22.20%
2026	-5.20 10.67% unlock
2027	-7.77 49.42% unlock
2028	88.07 1,233.46% unlock
2029	7.05 92.00% unlock
2030	4.30 39.01% unlock
2031	2.92 32.09% unlock
2032	2.85 2.40% unlock
2033	2.47 13.33% unlock

Vera Therapeutics Inc - Ordinary Shares - Class A...

Current Vera Therapeutics Inc - Ordinary Shares - Class A Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
JP Morgan	Locked ➜ Locked	Locked	Sep 08 2026
Wedbush	Locked ➜ Locked	Locked	Aug 17 2026
HC Wainwright & Co.	Locked ➜ Locked	Locked	Aug 12 2026
Wedbush	Locked ➜ Locked	Locked	Aug 11 2026
Guggenheim	Locked ➜ Locked	Locked	Jul 08 2026
HC Wainwright & Co.	Locked ➜ Locked	Locked	Jul 08 2026
TD Cowen	Locked ➜ Locked	Locked	Jul 08 2026

Analyst Rating	Date
Locked JP Morgan: Locked ➜ Locked	Sep 08 2026
Locked Wedbush: Locked ➜ Locked	Aug 17 2026
Locked HC Wainwright & Co.: Locked ➜ Locked	Aug 12 2026
Locked Wedbush: Locked ➜ Locked	Aug 11 2026
Locked Guggenheim: Locked ➜ Locked	Jul 08 2026
Locked HC Wainwright & Co.: Locked ➜ Locked	Jul 08 2026
Locked TD Cowen: Locked ➜ Locked	Jul 08 2026

Discover more stocks with a high price target

NIO ADR 104.57%

Alibaba Group Holding Ltd 70.15%

Rheinmetall 66.12%

Infineon 62.78%

Tencent Holdings Ltd. 56.53%

Adyen 53.79%

TUI 52.57%

Uber Technologies 47.97%

BYD 47.08%

Siemens Energy 46.63%

Adidas 42.38%

Deutsche Telekom 37.89%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now